Last reviewed · How we verify
NCT01373684: PAS
PEG-interferon Alfa-2a add-on Study in HBeAg Negative Chronic Hepatitis B Patients
Phase 4 trial testing Peginterferon alfa-2a in Chronic Hepatitis B in 90 participants. Completed in 28 October 2019.
28 October 2019
Quick facts
| Lead sponsor | Foundation for Liver Research |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 25 May 2012 |
| Primary completion | 28 October 2019 |
| Estimated completion | 28 October 2019 |
| Sites | 8 locations across Netherlands, Canada |
Drugs / interventions tested
- Peginterferon alfa-2a (PEGINTERFERON ALFA-2A) — full drug profile →
- Nucleos(t)ide analogue — full drug profile →
Conditions studied
- Chronic Hepatitis B — all drugs for Chronic Hepatitis B →
Sponsor
Foundation for Liver Research
Who can join
18 and older, any sex, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study intends to investigate whether addition of PEG-IFN alfa-2a in HBeAg-negative chronic hepatitis B patients who are pretreated with nucleos(t)ide analogues enhances the degree of HBsAg decline.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Chia, a large annotated corpus of clinical trial eligibility criteria.
Kury F, Butler A, Yuan C, Fu LH, et al · · 2020 · cited 31× · PMID 32855408 · DOI 10.1038/s41597-020-00620-0
Verify or expand the search:
- PubMed search for NCT01373684
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Peginterferon alfa-2a
Trials testing the same drug.
- NCT02364336 — Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment · Phase 2 · completed
- NCT02201407 — An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Ki · completed
- NCT01718301 — HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin · Phase 3 · terminated
- NCT01609049 — An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C a · completed
- NCT01667432 — An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hep · completed
Other recruiting trials for Chronic Hepatitis B
Currently open trials in the same condition.
- NCT07275918 — SA1211 Injection Phase 1 Study · Phase 1 · recruiting
- NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
- NCT07135349 — A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B · Phase 2 · active not recruiting
- NCT07307586 — A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatiti · Phase 3 · recruiting
- NCT07246889 — Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) · Phase 3 · active not recruiting
Other Foundation for Liver Research trials
Trials by the same sponsor.
- NCT03120195 — EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study · NA · completed
- NCT02292745 — Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Ad · NA · completed
- NCT01958190 — Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01373684 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Foundation for Liver Research
- Last refreshed: 8 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01373684.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing